Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
NCT04973670Phase 3Unknown
- Sponsor
- Southeast University
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and acute respiratory distress syndrome (ARDS) comparing Sivelestat sodium with Placebo (2 arms). Primary endpoint: Progression to Acute Respiratory Distress Syndrome at 7 days. Status: unknown.
02
Drugs
sivelestat
03
Conditions
sepsisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04973670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973670.